Editas Medicine, Inc.
A biotech company that develops treatments for serious diseases by editing genes with CRISPR, a molecular tool that snips and rewrites DNA. Founded in 2013 in Cambridge, Massachusetts, it was started by pioneers of the field including Jennifer Doudna and Feng Zhang, and its name comes from the Latin word "edit." Its medicines aim at inherited conditions such as blood disorders and cardiovascular disease.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 13GPassive | 5.8% | 8.89M | Aug 14, 2026 |
| Daniel Schneeberger | 13GPassive | 5.8% | 8.89M | Aug 14, 2026 |
| BlackRock, Inc. | 13G/APassive | 4.97% | 8.36M | Jul 29, 2026 |
| TCG Crossover GP III, LLC | 13GPassive | 9.9% | 15.80M | Jun 3, 2026 |
| TCG Crossover Fund III, L.P. | 13GPassive | 9.9% | 15.80M | Jun 3, 2026 |
| Chen Yu | 13GPassive | 9.9% | 15.80M | Jun 3, 2026 |
| RA Capital Management, L.P. | 13GPassive | 5.8% | 8.89M | Jun 3, 2026 |
| Peter Kolchinsky | 13GPassive | 5.8% | 8.89M | Jun 3, 2026 |
| Rajeev Shah | 13GPassive | 5.8% | 8.89M | Jun 3, 2026 |
| RA Capital Healthcare Fund, L.P. | 13GPassive | 5.8% | 8.89M | Jun 3, 2026 |